Rxivist logo

Novel 5-Hydroxymethylcytosine Markers for Pancreatic Cancer

By Chang Zeng, Zhou Zhang, Jun Wang, Brian C-H Chiu, Lifang Hou, Wei Zhang

Posted 25 Sep 2018
bioRxiv DOI: 10.1101/425983 (published DOI: 10.3390/epigenomes3030016)

OBJECTIVES: Robust biomarkers for pancreatic cancer (PaC) early detection/prognosis are critical for improved patient survival. Our goal was to explore the biomarker potential of 5-hydroxymethylcytosines (5hmC), an epigenetic marker with a distinct role in cancer pathobiology, yet under-investigated due largely to technical constraints. METHODS: We used the TAB-Array assay, a state-of-the-art technology to directly profile 5hmC at single base resolution with the Illumina EPIC array (>850,000 CpG sites) in 17 pairs of tumor/adjacent tissue samples from US patients. RESULTS: We demonstrated distinctive distributions of 5hmC in tissues, and substantial differences between tumor and adjacent tissues, suggesting their diagnostic/prognostic value of for PaC. CONCLUSION: This study established the potential of 5hmC as a novel epigenetic biomarker for PaC.

Download data

  • Downloaded 338 times
  • Download rankings, all-time:
    • Site-wide: 110,854
    • In cancer biology: 3,334
  • Year to date:
    • Site-wide: 104,641
  • Since beginning of last month:
    • Site-wide: 122,350

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide